Download PDF
Horm Metab Res 2015; 47(03): 220-224
DOI: 10.1055/s-0034-1394370
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

High Thyroid-Stimulating Hormone Level is Associated with the Risk of Developing Atherosclerosis in Subclinical Hypothyroidism

CX. Gao   *
1   Department of Ultrasonic diagnosis, Gansu Provincial Hospital, Lanzhou, China
,
B. Yang   *
2   Graduate School, Ningxia Medical University, Yinchuan, Ningxia, China
,
Q. Guo
3   Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China
,
L H Wei
4   Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, China
,
LM. Tian
3   Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China
› Author Affiliations
Further Information

Publication History

received 29 May 2014

accepted 24 September 2014

Publication Date:
05 November 2014 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of our study was to assess the potential role of thyroid-stimulating hormone (TSH) in the risk of developing atherosclerosis in subclinical hypothyroidism (SCH). A cohort of 240 SCH patients and 150 euthyroid volunteers were recruited for the study. SCH patients were stratified into 2 groups according to TSH levels (group A: TSH<10 mIU/l; group B: TSH>10 mIU/l). All subjects were examined for clinical and biochemical parameters. Visfatin, omentin-1, and circulating endothelial biomarkers were measured. Patients in group B received l-thyroxine replacement to achieve euthyroidism; after 6 months of euthyroidism all measurements were repeated. Patients with SCH had higher total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and C-reactive protein (CRP) levels and lower nitric oxide (NO) and omentin-1 levels compared to euthyroid subjects (all p<0.05). TC, LDL-C, and CRP decreased significantly, while NO and omentin-1 levels increased significantly after l-thyroxine replacement. Based on multivariate liner stepwise regression analysis, omentin-1 was independently correlated with BMI and TSH; NO was independently correlated with age, TSH, LDL-C, and omentin-1. High TSH level contributes to endothelial dysfunction in SCH, while TSH-induced decrease of omentin-1 provides a new link between SCH and atherogenic risk.

Key words

thyroid-stimulating hormone - adipokines - subclinical hypothyroidism
*

* The first two authors contributed equally to this work.


 

  • References

  • 1 Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Int Med 2000; 132: 270-278
    PubMedGoogle Scholar
  • 2 Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis. Am J Med 2006; 119: 541-551
    CrossrefPubMedGoogle Scholar
  • 3 Fietta P, Delsante G. Focus on adipokines. Theor Biol Forum 2013; 106: 103-129
    PubMedGoogle Scholar
  • 4 Rodriguez-Rodriguez E, Perea JM, Lopez-Sobaler AM, Ortega RM. Obesity, insulin resistance and increase in adipokines levels: importance of the diet and physical activity. Nutr Hospital 2009; 24: 415-421
    PubMedGoogle Scholar
  • 5 Northcott JM, Yeganeh A, Taylor CG, Zahradka P, Wigle JT. Adipokines and the cardiovascular system: mechanisms mediating health and disease. Canad J Physiol Pharmacol 2012; 90: 1029-1059
    CrossrefPubMedGoogle Scholar
  • 6 DeClercq V, Enns JE, Yeganeh A, Taylor CG, Zahradka P. Modulation of cardiovascular function by adipokines. Cardiovasc Hematol Disorders Drug Targets 2013; 13: 59-72
    PubMedGoogle Scholar
  • 7 Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol 2013; 216: T17-T36
    CrossrefPubMedGoogle Scholar
  • 8 Ntaios G, Gatselis NK, Makaritsis K, Dalekos GN. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013; 227: 216-221
    CrossrefPubMedGoogle Scholar
  • 9 Sorisky A, Bell A, Gagnon A. TSH receptor in adipose cells. Horm Metab Res 2000; 32: 468-474
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Gagnon A, Langille ML, Chaker S, Antunes TT, Durand J, Sorisky A. TSH signaling pathways that regulate MCP-1 in human differentiated adipocytes. Metabolism 2014; 63: 812-821
    CrossrefPubMedGoogle Scholar
  • 11 Antunes TT, Gagnon A, Bell A, Sorisky A. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obesity research 2005; 13: 2066-2071
    CrossrefPubMedGoogle Scholar
  • 12 Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-E1261
    CrossrefPubMedGoogle Scholar
  • 13 de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-1661
    CrossrefPubMedGoogle Scholar
  • 14 Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, Randeva HS. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008; 57: 801-808
    CrossrefPubMedGoogle Scholar
  • 15 Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011; 408: 339-343
    CrossrefPubMedGoogle Scholar
  • 16 Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Int Med 2010; 21: 530-535
    CrossrefPubMedGoogle Scholar
  • 17 Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol 2012; 76: 119-125
    CrossrefPubMedGoogle Scholar
  • 18 Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernandez-Real JM. Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring, Md) 2011; 19: 1552-1559
    CrossrefPubMedGoogle Scholar
  • 19 Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vascul Biol 2003; 23: 168-175
    CrossrefPubMedGoogle Scholar
  • 20 Donnini D, Ambesi-Impiombato FS, Curcio F. Thyrotropin stimulates production of procoagulant and vasodilative factors in human aortic endothelial cells. Thyroid 2003; 13: 517-521
    CrossrefPubMedGoogle Scholar
  • 21 Dardano A, Ghiadoni L, Plantinga Y, Caraccio N, Bemi A, Duranti E, Taddei S, Ferrannini E, Salvetti A, Monzani F. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 4175-4178
    CrossrefPubMedGoogle Scholar
  • 22 Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, Salvetti A, Ferrannini E, Monzani F. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003; 88: 3731-3737
    CrossrefPubMedGoogle Scholar
  • 23 Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovascul Dis (Basel, Switzerland) 2012; 34: 290-296
    PubMedGoogle Scholar
  • 24 Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22: 1200-1235
    CrossrefPubMedGoogle Scholar
  • 25 Turemen EE, Cetinarslan B, Sahin T, Canturk Z, Tarkun I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J 2011; 58: 349-354
    CrossrefPubMedGoogle Scholar
  • 26 Ozcan O, Cakir E, Yaman H, Akgul EO, Erturk K, Beyhan Z, Bilgi C, Erbil MK. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol 2005; 63: 203-206
    CrossrefPubMedGoogle Scholar
  • 27 Balzan S, Del Carratore R, Nicolini G, Beffy P, Lubrano V, Forini F, Iervasi G. Proangiogenic effect of TSH in human microvascular endothelial cells through its membrane receptor. J Clin Endocrinol Metab 2012; 97: 1763-1770
    CrossrefPubMedGoogle Scholar
  • 28 Tian L, Zhang L, Liu J, Guo T, Gao C, Ni J. Effects of TSH on the function of human umbilical vein endothelial cells. J Mol Endocrinol 2014; 52: 215-222
    CrossrefPubMedGoogle Scholar
  • 29 Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011; 219: 811-814
    CrossrefPubMedGoogle Scholar
  • 30 Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovascul Diabetol 2011; 10: 103
    PubMedGoogle Scholar
  • 31 Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and biophysical research communications 2010; 393: 668-672
    CrossrefPubMedGoogle Scholar
  • 32 Zhang YJ, Zhao W, Zhu MY, Tang SS, Zhang H. Thyroid-stimulating hormone induces the secretion of tumor necrosis factor-alpha from 3T3-L1 adipocytes via a protein kinase A-dependent pathway. Exp Clin Endocrinol Diabetes 2013; 121: 488-493
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Antunes TT, Gagnon A, Langille ML, Sorisky A. Thyroid-stimulating hormone induces interleukin-6 release from human adipocytes through activation of the nuclear factor-kappaB pathway. Endocrinology 2008; 149: 3062-3066
    CrossrefPubMedGoogle Scholar
  • 34 Santini F, Galli G, Maffei M, Fierabracci P, Pelosini C, Marsili A, Giannetti M, Castagna MG, Checchi S, Molinaro E, Piaggi P, Pacini F, Elisei R, Vitti P, Pinchera A. Acute exogenous TSH administration stimulates leptin secretion in vivo. Eur J Endocrinol 2010; 163: 63-67
    CrossrefPubMedGoogle Scholar